CN117603355A - 结合pd-1的抗体 - Google Patents

结合pd-1的抗体 Download PDF

Info

Publication number
CN117603355A
CN117603355A CN202311534081.9A CN202311534081A CN117603355A CN 117603355 A CN117603355 A CN 117603355A CN 202311534081 A CN202311534081 A CN 202311534081A CN 117603355 A CN117603355 A CN 117603355A
Authority
CN
China
Prior art keywords
antibody
amino acid
seq
fragment
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311534081.9A
Other languages
English (en)
Chinese (zh)
Inventor
岳海涛
林键
裴树军
梁世忠
李胜峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Thera Solutions Ltd
Original Assignee
Bio Thera Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Thera Solutions Ltd filed Critical Bio Thera Solutions Ltd
Publication of CN117603355A publication Critical patent/CN117603355A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
CN202311534081.9A 2019-04-10 2020-04-09 结合pd-1的抗体 Pending CN117603355A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910286677 2019-04-10
CN2019102866779 2019-04-10
CN202010275368.4A CN111808190B (zh) 2019-04-10 2020-04-09 结合pd-1的抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202010275368.4A Division CN111808190B (zh) 2019-04-10 2020-04-09 结合pd-1的抗体

Publications (1)

Publication Number Publication Date
CN117603355A true CN117603355A (zh) 2024-02-27

Family

ID=72750942

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311534081.9A Pending CN117603355A (zh) 2019-04-10 2020-04-09 结合pd-1的抗体
CN202010275368.4A Active CN111808190B (zh) 2019-04-10 2020-04-09 结合pd-1的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010275368.4A Active CN111808190B (zh) 2019-04-10 2020-04-09 结合pd-1的抗体

Country Status (7)

Country Link
US (1) US12466887B2 (enExample)
EP (1) EP3931223A4 (enExample)
JP (1) JP7641910B2 (enExample)
CN (2) CN117603355A (enExample)
AR (1) AR118619A1 (enExample)
TW (1) TWI916327B (enExample)
WO (1) WO2020207432A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026067821A1 (zh) * 2024-09-30 2026-04-02 百奥泰生物制药股份有限公司 一种抗pd-1抗体制剂及其制备方法和用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022007807A1 (zh) * 2020-07-07 2022-01-13 百奥泰生物制药股份有限公司 双特异性抗体及其应用
CN116437926B (zh) * 2020-10-11 2026-01-20 百奥泰生物制药股份有限公司 抗pd-1抗体在联合用药中的应用
EP4353746A4 (en) * 2021-06-11 2024-12-04 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
WO2025140324A1 (zh) 2023-12-26 2025-07-03 百奥泰生物制药股份有限公司 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
WO2025190251A1 (zh) * 2024-03-12 2025-09-18 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途
CN120919340A (zh) * 2024-05-09 2025-11-11 百奥泰生物制药股份有限公司 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用
CN121015902A (zh) * 2024-05-27 2025-11-28 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PL3368572T5 (pl) 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
EP3604539A4 (en) * 2017-03-27 2020-12-23 National University Corporation Hokkaido University ANTI-PD-L1 ANTIBODY FOR DETECTION OF PD-L1
WO2018217227A1 (en) * 2017-05-24 2018-11-29 Immunomedics, Inc. Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
CN108997499B (zh) * 2018-09-12 2020-07-31 首都医科大学附属北京胸科医院 一种抗人pd-l1抗体及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026067821A1 (zh) * 2024-09-30 2026-04-02 百奥泰生物制药股份有限公司 一种抗pd-1抗体制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP3931223A1 (en) 2022-01-05
EP3931223A4 (en) 2023-07-12
US12466887B2 (en) 2025-11-11
JP7641910B2 (ja) 2025-03-07
TW202104262A (zh) 2021-02-01
CN111808190A (zh) 2020-10-23
US20220204623A1 (en) 2022-06-30
AR118619A1 (es) 2021-10-20
CN111808190B (zh) 2023-12-12
WO2020207432A1 (en) 2020-10-15
TWI916327B (zh) 2026-03-01
JP2022538375A (ja) 2022-09-02

Similar Documents

Publication Publication Date Title
CN111808190B (zh) 结合pd-1的抗体
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
CN111655286A (zh) 作为免疫调节剂的cd96结合剂
TWI833244B (zh) 一種雙抗組合及其應用
TW202216768A (zh) Ｌａｉｒ－１結合劑及其使用方法
JP2024534795A (ja) 二重特異性抗体およびその使用
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
WO2023143535A1 (zh) 一种靶向il-18bp的抗体及其应用
AU2021446021A1 (en) Anti-bcam antibody or antigen-binding fragment thereof
WO2023236991A1 (zh) 靶向her2，pd-l1和vegf的三特异性抗体
WO2023045370A1 (zh) 靶向tigit的单克隆抗体
CN120230216B (zh) 抗lair1抗体及其用途
HK40033623A (en) Antibody binding to pd-1
HK40033623B (en) Antibody binding to pd-1
CN121108346B (zh) 抗ly6g6d单域抗体及其制备方法和用途
CN116333125A (zh) 结合死亡受体4和死亡受体5的抗体
WO2024193668A1 (zh) 抗ctla-4/抗tigit双特异性抗体及其应用
KR20240051277A (ko) PD-L1, CD137, 및/또는 TGFβ에 대한 이중특이체 및 삼중특이체 결합 단백질 및 이의 용도
WO2024193665A1 (zh) 抗pd-1/抗tigit双特异性抗体与il-2的融合蛋白及应用
WO2025056056A1 (zh) 药物组合及用途
HK40123044A (zh) 药物组合及用途
CN115785269A (zh) 抗pd-l1的抗体及其应用
HK40090273A (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
EA042365B1 (ru) Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: 510005, No. 18, Helix 2nd Road, International Biomedical Island, Huangpu District, Guangzhou City, Guangdong Province

Applicant after: BIO-THERA SOLUTIONS, Ltd.

Address before: 510530 Guangdong Guangzhou high tech Industrial Development Zone, Science City, open source road 11, A6 fifth.

Applicant before: BIO-THERA SOLUTIONS, Ltd.

Country or region before: China